| Author(s) | Valentino L; Pierre J
|
|---|
| Title | JAW/STAT signal transduction: Regulators and implication in hematological malignancies
|
|---|
| Source | BIOCHEMICAL PHARMACOLOGY 71 (6): 713-721
|
|---|
| Date | 2006 MAR 14
|
|---|
| Type | Journal : Review
|
|---|
| LCR: 3 NCR: 103 LCS: 1 GCS: 2
| | Comment |
|
|---|
| Address | Fac Pharm Chatenay Malabry, INSERM, U749, F-92296 Chatenay Malabry, France.
|
|---|
| Reprint | Pierre, J, Fac Pharm Chatenay Malabry, INSERM, U749, 5,Rue JB Clement,
F-92296 Chatenay Malabry, France.
|
|---|
| E-mail | josiane.pierre@cep.u-psud.fr
|
|---|
| Abstract | Signal transducers and activators of transcription (STATs) comprise a family of several transcription factors that are activated by a variety of cytokines, hormones and growth factors. STATs are activated through tyrosine phosphorylation, mainly by JAK kinases, which lead to their dimerization, nuclear translocation and regulation of target genes expression. Stringent mechanisms of signal attenuation are essential for insuring appropriate, controlled cellular responses. Among them phosphotyrosine phosphatases; (SHPs, CD45, PTP1B/TC-PTP), protein inhibitors of activated STATs (PIAS) and suppressors of cytokine signaling (SOCS) inhibit specific and distinct aspects of cytokine signal transduction. SOCS proteins bind through their SH2 domain to phosphotyrosine residues in either cytokine receptors or JAK and thus can suppress cytokine signaling. Many recent findings indicate that SOCS proteins act, in addition, as adaptors that regulate the turnover of certain substrates by interacting with and activating an E3 ubiquitin ligase. Thus, SOCS proteins act as negative regulators of JAK/STAT pathways and may represent tumour suppressor genes. The discovery of oncogenic partner in this signaling pathway, more especially in diverse hematologic malignancies support a prominent role of deregulated pathways in the pathogenesis of diseases. Fusion proteins implicating the JH1 domain of JAK2 (TEL-JAK2, BCR-JAK2), leading to deregulated activity of JAK2, have been described as the result of translocation. Somatic point mutation in JH2 domain of JAK2 (JAK2(V617F)), leading also to constitutive tyrosine phosphorylation of JAK2 and its downstream effectors was reported in myeloproliferative disorders. Furthermore, silencing of socs-1 and shp-1 expression by gene methylation is observed in some cancer cells. (c) 200S Elsevier Inc. All rights reserved.
|
|---|
| CR |
ARAKI T, 2004, NAT MED, V10, P849
AURORA T, 2003, J BIOL CHEM, V278, P21327
BANVILLE D, 1995, GENOMICS, V27, P165
BAXTER EJ, 2005, LANCET, V365, P1054
BOUSQUET M, 2005, ONCOGENE, V24, P7248
BRAKENSIEK K, 2005, BRIT J HAEMATOL, V130, P209
BROMBERG J, 2002, J CLIN INVEST, V109, P1139
CATLETTFALCONE R, 1999, IMMUNITY, V10, P105
CHEN XP, 2002, P NATL ACAD SCI USA, V99, P2175
CHENG WW, 2001, J PAEDIATR CHILD H, V37, P300
CHIM CS, 2004, BLOOD, V103, P4630
CHUNG CD, 1997, SCIENCE, V278, P1803
DARNELL JE, 1997, SCIENCE, V277, P1630
DECKER T, 2000, ONCOGENE, V19, P2628
DESEPULVEDA P, 1999, EMBO J, V18, P904
EKMEKCI CG, 2004, AM J HEMATOL, V77, P233
ENDO TA, 1997, NATURE, V387, P921
FISCHER P, 2004, BIOCHEM J 2, V378, P449
FRANGIONI JV, 1992, CELL, V68, P545
FRANTSVE J, 2001, MOL CELL BIOL, V21, P3547
FUJITAKE S, 2004, J GASTROENTEROL, V39, P120
FUKUSHIMA N, 2003, BRIT J CANCER, V89, P338
GALM O, 2003, BLOOD, V101, P2784
GIRAULT JA, 1998, MOL MED, V4, P751
GOLUB TR, 1996, MOL CELL BIOL, V16, P4107
GREENHALGH CJ, 2002, J BIOL CHEM, V277, P40181
GRIESINGER F, 2005, GENE CHROMOSOME CANC, V44, P329
GUITER C, 2004, BLOOD, V104, P543
HEBENSTREIT D, 2003, J IMMUNOL, V171, P5901
HERMAN JG, 2003, NEW ENGL J MED, V349, P2042
HERMISTON ML, 2003, ANNU REV IMMUNOL, V21, P107
HORVAI AE, 1997, P NATL ACAD SCI USA, V94, P1074
JAMES C, 2005, NATURE, V434, P1144
JEGALIAN AG, 2002, J BIOL CHEM, V277, P2345
JOHAN MF, 2005, BRIT J HAEMATOL, V129, P60
JOHANNES JM, 1995, PEDIATR HEMAT ONCOL, V12, P571
JONES PA, 1999, NAT GENET, V21, P163
JOOS S, 2003, INT J CANCER, V103, P489
KAMIZONO S, 2001, J BIOL CHEM, V276, P12530
KAMPA D, 2000, BIOCHEM BIOPH RES CO, V278, P175
KILE BT, 2002, TRENDS BIOCHEM SCI, V27, P235
KISHIMOTO T, 2001, NAT GENET, V28, P4
KRALOVICS R, 2005, NEW ENGL J MED, V352, P1779
LACRONIQUE V, 1997, SCIENCE, V278, P1309
LACRONIQUE V, 2000, BLOOD, V95, P2076
LEONARD WJ, 1998, ANNU REV IMMUNOL, V16, P293
LEVINE RL, 2005, CANCER CELL, V7, P387
LI B, 2001, CANCER RES, V61, P8014
LIN SY, 2004, ONCOL REP, V11, P341
LITTERST CM, 2002, J BIOL CHEM, V277, P36052
LIU B, 1998, P NATL ACAD SCI USA, V95, P10626
LIU B, 2001, P NATL ACAD SCI USA, V98, P3203
LIU B, 2004, NAT IMMUNOL, V5, P891
LIU E, 2003, EMBO J, V22, P5036
LIU TC, 2003, BRIT J HAEMATOL, V123, P654
LUO H, 1997, MOL CELL BIOL, V17, P1562
MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587
MELZNER I, 2005, BLOOD, V105, P2535
MELZNER I, 2005, INT J CANC
MIYOSHI H, 2004, J GASTROENTEROL, V39, P563
MIYOSHI H, 2005, J HEPATOL, V43, P757
NAGAI H, 2003, J HUM GENET, V48, P65
NAKA T, 1997, NATURE, V387, P924
NIWA Y, 2005, ONCOGENE, V24, P6406
OKA T, 2002, CANCER RES, V62, P6390
OKOCHI O, 2003, CLIN CANCER RES, V9, P5295
OSHIMO Y, 2004, INT J CANCER, V112, P1003
PEETERS P, 1997, BLOOD, V90, P2535
REITER A, 2005, CANCER RES, V65, P2662
ROTH W, 2004, J IMMUNOL, V173, P6189
ROTTAPEL R, 2002, ONCOGENE, V21, P4351
RUI LY, 2002, J BIOL CHEM, V277, P42394
SAHARINEN P, 2000, MOL CELL BIOL, V20, P3387
SAITO H, 2000, J IMMUNOL, V164, P5833
SCHMIDT D, 2002, P NATL ACAD SCI USA, V99, P2872
SCHMITZ J, 2000, J BIOL CHEM, V275, P12848
SHUAI K, 2005, NAT REV IMMUNOL, V5, P593
SILVER DL, 2004, CANCER RES, V64, P3550
STARR R, 1997, NATURE, V387, P917
STEENSMA DP, 2005, BLOOD, V106, P1207
STEPHANOU A, 2003, INT J EXP PATHOL, V84, P239
SUTHERLAND KD, 2004, ONCOGENE, V23, P7726
TARTAGLIA M, 2003, NAT GENET, V34, P148
TENHOEVE J, 2002, MOL CELL BIOL, V22, P5662
TO KF, 2004, BRIT J CANCER, V91, P1335
TRAVAGLI J, 2004, J BIOL CHEM, V279, P35182
TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85
UEDA M, 2003, BRIT J HAEMATOL, V123, P288
UEHARA E, 2003, INT J ONCOL, V23, P693
UNGUREANU D, 2002, MOL CELL BIOL, V22, P3316
VALINEVA T, 2005, J BIOL CHEM, V280, P14989
VERDIER F, 1998, J BIOL CHEM, V273, P28185
VERDIER F, 1998, MOL CELL BIOL, V18, P5852
VUONG BQ, 2004, MOL CELL BIOL, V24, P9092
WATANABE D, 2004, BRIT J HAEMATOL, V126, P726
WEBER A, 2005, ONCOGENE, V24, P6699
YOSHIKAWA H, 2001, NAT GENET, V28, P29
YOSHIMURA A, 1995, EMBO J, V14, P2816
ZHANG JG, 1999, P NATL ACAD SCI USA, V96, P2071
ZHANG JJ, 1996, P NATL ACAD SCI USA, V93, P15092
ZHANG Q, 2002, J IMMUNOL, V168, P466
ZHANG Q, 2005, P NATL ACAD SCI USA, V102, P6948
ZHAO RX, 2005, J BIOL CHEM, V280, P22788
|
|---|
|